11 COPD Clinical Trials in Phoenix, AZ (2026)

Q: How do I join a clinical trial in Phoenix?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you.

Recruiting COPD Studies in Phoenix

NCT06283966Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with...

Phoenix, AZPHASE35,000 participantsAstraZeneca

View Study Details

NCT07363694Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breath...

Phoenix, AZPHASE21,156 participantsPfizer

View Study Details

NCT06878261Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive...

Phoenix, AZPHASE3990 participantsAstraZeneca

View Study Details

NCT06883305Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD

Phoenix, AZPHASE3990 participantsAstraZeneca

View Study Details

NCT07082738Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive p...

Phoenix, AZPHASE2987 participantsAstraZeneca

View Study Details

NCT07190209Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged...

Phoenix, AZPHASE3942 participantsSanofi

View Study Details

NCT06388421Recruiting

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD)....

Phoenix, AZ900 participantsUnited Therapeutics

View Study Details

NCT07684820Recruiting

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study dru...

Phoenix, AZPHASE2600 participantsExpedition Therapeutics, Inc

View Study Details

NCT07285655Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3)...

Phoenix, AZPHASE3344 participantsLiquidia Technologies, Inc.

View Study Details

NCT06035120Recruiting

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe. Subjects will undergo ...

Phoenix, AZNA200 participantsPulmonx Corporation

View Study Details

NCT04302272Recruiting

STRIVE Post-Market Registry Study

This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-m...

Phoenix, AZ150 participantsOlympus Corporation of the Americas

View Study Details

About COPD Clinical Trials in Phoenix

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that makes breathing difficult, primarily caused by smoking. It includes emphysema and chronic bronchitis. Treatment involves bronchodilators, inhaled steroids, pulmonary rehabilitation, and oxygen therapy.

There are currently 11 copd clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 12,259 participants. Research is being sponsored by AstraZeneca, Pfizer, Sanofi and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

COPD Clinical Trials in Phoenix — FAQ

Are there copd clinical trials in Phoenix?

Yes, there are 11 copd clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What copd treatments are being tested?

The 11 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for copd.

Data updated September 7, 2026 from ClinicalTrials.gov